Key result
Review outlines viral entry inhibitors for HIV and RSV, detailing mechanisms and new AIDS therapy candidates.
Why the study?
New anti-HIV drugs are needed due to side effects and resistance to current HAART regimens, prompting review of viral entry and RSV fusion inhibitors.
This review summarizes different classes of viral entry inhibitors for HIV and RSV fusion inhibitors, highlighting their mechanisms and new candidates for therapy.
Answers are grounded in this paper and cite their sources.
May guide antiviral design for HIV/RSV; leaves open clinical validation of new entry inhibitors.
The therapeutic approach to AIDS is based on the combination of different drugs in the highly active antiretroviral therapy (HAART) regimen. These drugs have a wide variety of side effects, and some strains of HIV can develop resistance: for these reasons new anti-HIV drugs are needed. In the wide field of anti-HIV medicine this review covers different classes of drugs which inhibit viral entry: in particular the classification of main categories, their mode of action and some new candidates for AIDS therapy are contemplated. Also covered in this review are respiratory syncytial virus (RSV) fusion inhibitors.
No takes yet. Share an insight, caveat, or question.
Murineddu et al. (2010) conducted a review in AIDS/HIV and RSV. Viral entry and RSV fusion inhibitors was evaluated. This review outlines different classes of viral entry inhibitors for HIV and RSV, detailing their classification, mode of action, and new candidates for AIDS therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: